Search

Displaying results 601 - 610 of 4626 in total
  1. Drug

    Ataluren

    go.drugbank.com/drugs/DB05016
    ApprovedWithdrawn

    This drug does not yet have approval by the US Food and Drug Administration or by Health Canada for any indications. … Ataluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk.

  2. Drug

    Cemiplimab

    go.drugbank.com/drugs/DB14707
    ApprovedInvestigational

    By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses. … [L39804] Cemiplimab was also approved by the European Commission on June 28, 2019.

  3. Drug

    Epcoritamab

    go.drugbank.com/drugs/DB16672
    ApprovedInvestigational

    [A259736,A258488] The use of epcoritamab in this group of patients has high response rates, durable complete responses and manageable adverse events with few discontinuations. … In May 2023, epcoritamab was approved by the FDA under accelerated approval for the treatment of relapsed or refractory DLBCL.

  4. Drug

    Desogestrel

    go.drugbank.com/drugs/DB00304
    ApprovedInvestigational

    [A176342] The first approved drug containing desogestrel was developed by Organon USA Inc in 1972 and FDA approved in 1992.[L5762]

  5. Drug

    Peanut oil

    go.drugbank.com/drugs/DB13964
    ApprovedWithdrawn

    The kernels are consumed roasted but a large percentage is used for the production of vegetable oil.

  6. Drug

    Almotriptan

    go.drugbank.com/drugs/DB00918
    Approved

    It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that cause pain, nausea, and other symptoms

  7. Drug

    Diphenylpyraline

    go.drugbank.com/drugs/DB01146
    Approved

    Antihistamines prevent, but do not reverse, responses mediated by histamine alone. … Antihistamines used in the treatment of allergy act by competing with histamine for H 1-receptor sites on effector cells.

  8. Drug

    Darolutamide

    go.drugbank.com/drugs/DB12941
    ApprovedInvestigational

    [A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.[L10887] … The goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and life expectancy for those with advanced prostate cancer.

  9. Drug

    Metoclopramide

    go.drugbank.com/drugs/DB01233
    ApprovedInvestigational

    [T683] Metoclopramide was initially approved by the FDA in 1980.[A184922] … Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system.

  10. Drug

    Nirmatrelvir

    go.drugbank.com/drugs/DB16691
    ApprovedInvestigational

    [L33359] Both drugs were inhibitors of SARS-CoV-2 3CL<sup>PRO</sup>, but nirmatrelvir has the advantage of being orally bioavailable. … [L39544] It was fully approved by the FDA on May 25, 2023.